ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01745094
Recruitment Status : Completed
First Posted : December 7, 2012
Results First Posted : February 28, 2018
Last Update Posted : February 28, 2018
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc

December 6, 2012
December 7, 2012
December 10, 2017
February 28, 2018
February 28, 2018
October 1, 2012
July 23, 2013   (Final data collection date for primary outcome measure)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: From first dose of study drug up to weeks 16 ]
TEAEs were defined as AEs observed after the first administration of the study drugs for the treatment period. The investigator assessed the severity of AEs, including abnormal clinical laboratory values, Electrocardiogram (ECG), vital signs, as follows: Mild: No disruption of normal daily activities; Moderate: Affected normal daily activities; Severe: Inability to perform daily activities. A drug-related TEAE was a TEAE with at least a possible relationship to the study drug as assessed by the investigator.
Safety assessed by the incidence of adverse events, vial signs labo-tests, 12-lead ECGs, QTc-intervals Urine volume and uroflowmetry [ Time Frame: for 16 Weeks ]
Complete list of historical versions of study NCT01745094 on ClinicalTrials.gov Archive Site
  • Change From Baseline in OABSS Total Score [ Time Frame: Baseline and week 8, 16 ]
    The OABSS questionnaire was a questionnaire completed by participants with 4 questions regarding their OAB symptoms. For each participant, the OABSS total score was calculated from the sum total of the score of each question. The total score ranges from 0 to 15 with higher score indicating more symptoms. The OABSS data obtained at week 0 were used as baseline.
  • Number of Participants Who Achieved Normalization for OABSS Total Score [ Time Frame: Week 8 and 16 ]
    Normalization for OABSS Total Score was defined as OABSS total score ≤ 2 or OABSS Question 3 score ≤ 1.
  • Change From Baseline in Overactive Bladder Questionnaire Short Form (OAB-q SF) Severity Score [ Time Frame: Baseline and week 8, 16 ]
    The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the Health-related Quality of Life (HRQL). The Severity Symptom section included 6 questions. For each participant, the symptom severity score was derived as a sum of scores for Questions 1 to 6. The total score ranges from 6 to 36 with higher symptom severity score indicating greater symptom bother. OAB-q SF data obtained at week 0 visit were used as baseline.
  • Change From Baseline in OAB-q SF Total HRQL Score [ Time Frame: Baseline and week 8, 16 ]
    The OAB-q SF questionnaire was a questionnaire completed by participants composed of 2 sections: Severity Symptom and the HRQL. The HRQL section included 13 questions. For each participant, the total HRQL score was derived as a sum of scores for Questions 7 to 19. The total score ranges from 13 to 78 with higher total HRQL score indicating greater HRQL. OAB-q SF data obtained at week 0 visit were used as baseline.
  • Change From Baseline in the Number of Micturitions Per 24 Hours [ Time Frame: Baseline and week 4, 8, 12, 16 ]
    Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean number of micturitions per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable "urinated" was indicated, divided by the number of days on which episodes were recorded.
  • Number for Participants Who Achieved Normalization of the Number of Micturitions Per 24 Hours [ Time Frame: Week 16 ]
    Normalization for the mean number of micturitions per 24 hours was defined as < 8 micturitions per 24 hours.
  • Change From Baseline in the Number of Urgency Episodes Per 24 Hours [ Time Frame: Baseline and week 4, 8, 12, 16 ]
    Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urgency episode was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable "urgency" was indicated, divided by the number of days on which episodes were recorded. Only participants who had an urgency episode at baseline was included in the analysis.
  • Number for Participants Who Achieved Normalization of the Number of Urgency Episodes Per 24 Hours [ Time Frame: Week 16 ]
    Normalization for the mean number of urgency episodes per 24 hours was defined as no urgency episode per 24 hours.
  • Change From Baseline in the Number of Incontinence Episodes Per 24 Hours [ Time Frame: Baseline and week 4, 8, 12, 16 ]
    Participants completed the patient diary (paper document) for 3 days immediately before each visit. An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable "urinary incontinence'" was indicated, divided by the number of days on which episodes were recorded. Only participants who had an incontinence episode at baseline was included in the analysis.
  • Number for Participants Who Achieved Normalization of the Number of Incontinence Episodes Per 24 Hours [ Time Frame: Week 16 ]
    Normalization for the mean number of incontinence episodes per 24 hours was defined as no incontinence episode per 24 hours.
  • Change From Baseline in the Number of Urge Incontinence Episodes Per 24 Hours [ Time Frame: Baseline and week 4, 8, 12, 16 ]
    Participants completed the patient diary (paper document) for 3 days immediately before each visit. An urge incontinence episode was defined as any episode when both urgency and incontinence occurred concurrently. The mean number of incontinence episodes per 24 hours was calculated by taking the sum of all marked episodes in the patient diary where the variable "urgency" and "urinary incontinence'" were indicated, divided by the number of days on which episodes were recorded. Only participants who had an urge incontinence episode at baseline was included in the analysis.
  • Change From Baseline in the Volume Voided Per Micturition [ Time Frame: Baseline and week 8, 16 ]
    Participants completed the patient diary (paper document) for 3 days immediately before each visit. The mean volume per micturition was calculated by taking the sum of the urinary volumes where the volume voided was > 0 and where "urinary incontinence" was not indicated in the patient diary, divided by the number of micturitions where the volume voided was > 0 and where "urinary incontinence" was not indicated. Only participants who had volume voided was > 0 at baseline was included in the analysis.
  • Change From Baseline in the Number of Nocturia Episodes Per Night [ Time Frame: Baseline and week 4, 8, 12, 16 ]
    Participants completed the patient diary (paper document) for 3 days immediately before each visit. A nocturia episode was defined as waking at night 1 or more times to void. Night time was defined as the period between bedtime and the wake-up time the following day (micturitions at the same time as the wake-up time were excluded). The mean number of nocturia episodes per night was calculated by taking the sum of nocturia episodes in the patient diary where the variable "urinated" was indicated during the night time, divided by the number of nights. Only participants who had a nocturia episode at baseline was included in the analysis.
  • Change From Baseline in Postvoid Residual (PVR) Volume [ Time Frame: Baseline and week 4, 8, 12, 16 ]
    Measurement of PVR volume was made using either ultrasonography or urethral catheterization, provided that the same method was used for the same participant throughout the study.
  • Change from baseline in OABSS (OverActive Bladder Symptom Score) [ Time Frame: Baseline and Week 16 ]
  • Change from baseline in OAB-q (OverActive Bladder questionnaire) short form (QAB-q SF) score [ Time Frame: Baseline and Week 16 ]
  • Change from baseline in mean number of micturition episodes per 24 hour [ Time Frame: Baseline and Week 16 ]
  • Change from baseline in mean number of urgency episodes per 24 hours [ Time Frame: Baseline and Week 16 ]
  • Change from baseline in mean number of urinary incontinence episodes per 24 hours [ Time Frame: Baseline and Week 16 ]
  • Change from baseline in mean volume voided per micturition [ Time Frame: Baseline and Week 16 ]
Not Provided
Not Provided
 
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan
The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.
The total duration of the study was 18 weeks, comprising a 2-week screening period and a 16-week treatment period. Patients meeting the eligibility criteria for provisional enrollment received the study drug for the screening period (solifenacin) at the same dose as that before the start of the study (2.5 or 5 mg), once daily after breakfast orally for 2 weeks. After the screening period, patients meeting the eligibility criteria for formal enrollment received the study drugs for the treatment period (solifenacin 2.5 or 5 mg and mirabegron 25 mg), once daily after breakfast orally for 16 weeks. Mirabegron dose could be increased to 50 mg at week 8 visit if the patients met all of the following criteria: (1) had an inadequate response to mirabegron at the dose of 25 mg; (2) was judged by the investigator or coinvestigator to have no safety concerns; and (3) agreed to increase the dose.
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Overactive Bladder
  • Drug: mirabegron
    oral
    Other Names:
    • YM178
    • Betanis
  • Drug: solifenacin
    oral
    Other Names:
    • Vesicare
    • YM905
Experimental: Concomitant Group
concomitant administration of mirabegron to solifenacin treated patients
Interventions:
  • Drug: mirabegron
  • Drug: solifenacin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
223
200
July 23, 2013
July 23, 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female: postmenopausal OAB outpatient
  • Male: OAB outpatient who did not wish to have children at all
  • Patient had been treated with solifenacin at a stable dose once daily for at least 4 weeks prior to the study
  • Patient had a total OAB symptom score (OABSS ) score of ≥3 points and a Question 3 score ≥2 points

Exclusion Criteria:

  • Patient had a residual urine volume of ≥100 mL or a maximum flow rate <5 mL/s, or patients with benign prostatic hyperplasia, or lower urinary tract obstruction
  • Patient had serious heart disease (myocardial infarction, cardiac failure, uncontrolled angina pectoris, serious arrhythmia, use of pacemaker, etc.), liver disease, kidney disease, immunological disease, lung disease, etc. or patient had malignant tumor (except for malignant tumor that has not been treated for at least 5 y before the start of the screening period with no risk of recurrence)
  • Patient had received surgical therapy that may affect the urinary tract function within 24 weeks before the start of the screening period
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01745094
178-CL-110
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Not Provided
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Director: Medical Director Astellas Pharma Inc
Astellas Pharma Inc
December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP